33 news items
Page 2 of 2
uk6e0eqxcnrxwx8lqewiflbf
OCGN
8 Apr 24
across various disease stages.
With orphan drug and RMAT designations already secured, Ocugen targets BLA approval for OCU400 by 2026
xh5hayjcn4dz0sx7swbulmpm5njj4q
OCGN
8 Apr 24
remains on track for the 2026 BLA approval target. AboutĀ OCU400OCU400 is the Company's
vho2i1 hypip89eqga
OCGN
5 Apr 24
have significant limitations, as they require multiple injections per year and only target one pathway contributing to GA. OCU410 regulates multiple
ylu3zv
OCGN
3 Apr 24
delivery.
Additionally, enrollment and dosing progress were noted in OCU410 and OCU410ST trials targeting conditions like dry Age-Related Macular
2yb w9jm17zzstl2jvt4eeigw9j30pomlpj
ALTM
ATAI
CALM
3 Apr 24
Ramakanth reiterated Ocugen with a Buy and maintained a $7 price target.
Pyxis Oncology, Inc
23a9o04cjfsxizl6sizeli8e0pkn8nfc7m8l0b70zf4rfqi4vn
OCGN
3 Apr 24
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Ocugen (NASDAQ:OCGN) with a Buy and maintains $7 price target.
2jfwfe 56h624mp3zihk9uujr5lmh4aed0koy13vmqg1epz
OCGN
2 Apr 24
options have significant limitations, as they require multiple injections per year (impacting compliance) and only target one pathway contributing to GA
ided2q7f1zv 1b3mmofbspvfgbncoleqzy
APLT
BTBT
CIFR
1 Apr 24
declining over 8% on Thursday. Cantor Fitzgerald analyst Josh Siegler maintained Cleanspark with an Overweight and raised the price target from $10 to $20
yim4wsswlh izwmupliokaryqx
ABBV
AEHR
AKAN
25 Mar 24
offering.
Target Hospitality Corp. (NASDAQ:TH) jumped 21.3
bmxnpq2axf694piq6g00ys5zx56tsiq3f369328oy5vhh0j64dgflvj055wv
ABTS
AIR
ALAB
22 Mar 24
upgraded Foot Locker from Sell to Neutral and announced a $24 price target.
Losers
BYND
p8ppuuw3uwzisiob08osn
ALAB
ANNX
CGC
22 Mar 24
Lejuez upgraded Foot Locker from Sell to Neutral and announced a $24 price target.
Now Read This: Top 3 Materials Stocks That Could Blast Off In Q1
dywc9duzkf0l7kbjim25vsc9if5owvo3lmfcscsa25jl5crvl4
ALAB
ARGX
ARRY
21 Mar 24
upgraded the stock from Market Perform to Outperform and raised its price target from $1,400 to $1,500.
Fabrinet
5oyh4ufhml4hla1r10 nxg6pef6
OCGN
13 Mar 24
of GA, both require approximately 6-12 intravitreal injections annually and target only the complement system. OCU410 addresses multiple pathways causing